论文部分内容阅读
为探索Ｐ１６蛋白表达与肺癌（ＰＰＣ）的关系，作者应用免疫组织化学技术检测６５例ＰＰＣ组织中Ｐ１６蛋白的表达。结果显示：ＰＰＣ中Ｐ１６蛋白表达的总丢失率为３６．９２％±１８．４５％，其中腺癌（ＡＣ）组为２８．４７％±１６．３３％、鳞状细胞癌（ＳＣＣ）组为３５．９５％±１７．３６％、腺鳞癌（ＡＳＣＣ）组为５７．８８％±１０．１８％。其中６０岁以下组ＳＣＣ与６０岁以上组ＳＣＣ、低分化癌与中分化癌的Ｐ１６蛋白丢失率比较，以及ＡＣ与ＡＳＣＣ，ＳＣＣ与ＡＳＣＣ的Ｐ１６蛋白表达丢失率比较，其差异有显著性（Ｐ＜０．０５）。男性ＰＰＣ与女性ＰＰＣ、左肺ＰＰＣ与右肺ＰＰＣ、以及淋巴结转移性癌与原发性ＰＰＣ的Ｐ１６蛋白表达丢失率比较，其差异无显著性（Ｐ＞０．０５）。本研究结果提示Ｐ１６蛋白可能是ＰＰＣ预后判定的重要指标之一。
To explore the relationship between P16 protein expression and lung cancer (PPC), the authors used immunohistochemistry to detect the expression of P16 protein in 65 PPC tissues. The results showed that the total loss rate of P16 protein expression in PPC was 36.92%±18.45%, among which the adenocarcinoma (AC) group was 28.47%±16.33%, and the squamous cell carcinoma (SCC) group was 35.95% ± 17.36% and adenosquamous carcinoma (ASCC) group were 57.88% ± 10.18%. The loss rate of P16 protein between SCC, poorly differentiated and moderately differentiated cancers in the 60-year-old group and 60-year-old group, and the loss rate of P16 protein expression in AC and ASCC, SCC, and ASCC were significant (P>0.05). <0.05). There was no significant difference in P16 protein expression loss between male PPC and female PPC, left lung PPC and right lung PPC, and metastatic lymph node metastasis and primary PPC (P>0.05). The results of this study suggest that P16 protein may be one of the important indicators of the prognosis of PPC.